About Generate Biomedicines
Generate Biomedicines is a therapeutics company. It focuses on a machine learning-powered generative biology platform to create new drugs on demand across a wide range of biological modalities. It was founded in 2018 and is based in Somerville, Massachusetts.
ESPs containing Generate Biomedicines
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI antibody discovery & development platforms market is an innovative field that utilizes artificial intelligence and machine learning algorithms to streamline and optimize the process of discovering and developing antibodies for therapeutic use. This market offers a range of solutions that enable the rapid identification of potential targets and the design of optimized antibody candidates. By…
Research containing Generate Biomedicines
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Generate Biomedicines in 1 CB Insights research brief, most recently on Aug 29, 2023.
Expert Collections containing Generate Biomedicines
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Generate Biomedicines is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Latest Generate Biomedicines News
Sep 14, 2023
14-09-2023 A company founded by Flagship Pioneering, Generate Biomedicines, has raised over a quarter of a billion dollars in a series C financing round. Launched in 2020 after two years of foundational research in Flagship’s Labs unit, the company is using a machine-learning-powered generative biology platform to develop novel therapeutics. The financing round attracted a number of new investors including Amgen (Nasdaq: AMGN), NVentures and MAPS Capital,… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Generate Biomedicines Frequently Asked Questions (FAQ)
When was Generate Biomedicines founded?
Generate Biomedicines was founded in 2018.
Where is Generate Biomedicines's headquarters?
Generate Biomedicines's headquarters is located at 101 South Street, Somerville.
What is Generate Biomedicines's latest funding round?
Generate Biomedicines's latest funding round is Series C.
How much did Generate Biomedicines raise?
Generate Biomedicines raised a total of $643M.
Who are the investors of Generate Biomedicines?
Investors of Generate Biomedicines include T. Rowe Price, ARCH Venture Partners, Fidelity Investments, Abu Dhabi Investment Authority, Flagship Pioneering and 11 more.
Who are Generate Biomedicines's competitors?
Competitors of Generate Biomedicines include JURA Bio and 3 more.
Compare Generate Biomedicines to Competitors
XtalPi provides quantum physic-based artificial intelligence (AI) for drug research and development. It offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi was founded in 2014 and is based in Shenzhen, China.
Therapeutics Data Commons (TDC) is a resource to access and evaluate AI methods, supporting the development of AI methods. It develops therapeutics to cure diseases and improve human health, which is the overarching goal of biomedical research. It provides intuitive, high-level APIs for both beginners and experts to create ML models in Python. It was founded in 2021 and is based in Cambridge, Massachusetts.
LabGenius operates as a drug discovery company that focuses on the discovery of next-generation protein therapeutics. The company’s discovery platform, economic value added (EVA), integrates technologies including artificial intelligence (AI), robotic automation, and synthetic biology. The company was founded in 2012 and is based in London, England.
BigHat Biosciences operates as a biotechnology company. It develops antibody therapies for patients using machine learning and synthetic biology and also offers antibody therapies to treat intractable conditions from chronic illnesses to life-threatening diseases. It was founded in 2019 and is based in San Mateo, California.
Adimab engages in the discovery, maturation, and production of therapeutic human antibodies. It integrates various aspects of antibody discovery and different screening methods that help discover high-affinity antibodies behaving well in a formulation and manufacturing context. The company was founded in 2007 and is based in Lebanon, New Hampshire.
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.